Compare AbbVie Inc (ABBV) vs ON Holding AG (ONON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ON Holding AG — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while ON Holding AG trades at $36.29 (market cap $12.21B). The key difference: AbbVie Inc is far larger — about 36.8× ON Holding AG's market cap, and AbbVie Inc pays a 2.72% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| ABBV | ONON | |
|---|---|---|
Market Cap | $449.91B | $12.21B |
Sector | Health | Technology |
52-Week High | $261.07 | $54.24 |
52-Week Low | $184.85 | $31.88 |
Enterprise Value | $513.38B | $11.53B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
ONON trades at $36.87, up 0.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 63.88% gross margin and 15.5% ROE, supported by revenue growth to $3.01B in 2025. Analyst consensus is bullish with a $47.33 price target, though technical indicators suggest near-term resistance.
The outlook remains positive given consistent earnings outperformance and raised profit guidance, but risks include tariff concerns and competitive pressures. Upside potential exists if the company maintains its innovation-led growth, particularly in Asia-Pacific markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
